TAT and cytokine responses 8 hours after LPS
Treatments and genotype by sex and strain . | No. of mice . | TAT, ng/mL (SD) . | IL-6, ng/mL (SD) . | MIP-2, ng/mL (SD) . | MCP-1, ng/mL (SD) . | IL-10, pg/mL (SD) . |
|---|---|---|---|---|---|---|
| F, C57BL/6 | ||||||
| Thrombin inhibition, high-dose LPS | ||||||
| wt, saline/saline | 8 | 1.6 (0.96) | 0 (7.6) | 0 (3.4) | 0.27 (0.38) | 13.7 (5.9) |
| wt, saline/LPS | 8 | 78.5 (43.1) | 406 (325) | 151 (92.5) | 568 (551) | 793 (432) |
| wt, 5 mg/kg hirudin/LPS | 7 | 0.78 (0.37)* | 484 (333) | 199 (82.5) | 729 (589) | 1109 (458) |
| Thrombin inhibition, low-dose LPS | ||||||
| wt, saline/LPS | 8 | 48.7 (30.0) | 142 (84.4) | 94.2 (68.8) | 205 (120) | 781 (318) |
| wt, 1 mg/kg hirudin/LPS | 8 | 14.2 (3.96)* | 65.9 (27.7) | 39.5 (19.6) | 104 (32.9) | 865 (284) |
| wt, 5 mg/kg hirudin/LPS | 6 | 4.29 (0.49)* | 88.7 (61.5) | 50.6 (40.0) | 112 (45.8) | 1188 (1072) |
| Par2/Par4 low-dose LPS | ||||||
| wt: no pretreatment/LPS | 6 | 80.6 (32.0) | 57.7 (48.7) | 31.3 (29.4) | 167 (96.2) | 1101 (579) |
| ko: no pretreatment/LPS | 7 | 91.7 (52.9) | 44.5 (11.7) | 36.9 (23.6) | 133 (54.3) | 932 (423) |
| Thrombocytopenia low-dose LPS | ||||||
| wt, control serum/LPS | 8 | 64.8 (19.0) | 67.5 (36.7) | 47.2 (32.9) | 113 (58.4) | 905 (491) |
| wt, antiplatelet serum/LPS | 8 | 72.6 (13.9) | 110 (40.5) | 53.8 (19.7) | 139 (29.9) | 1464 (731) |
| M, 129/C57BL/6 | ||||||
| Thrombin inhibition PAR2 littermates, low-dose LPS | ||||||
| wt, 1 mg/kg hirudin/LPS | 11 | 2.8 (1.5) | 34.2 (29.5) | ND | ND | ND |
| ko, 1 mg/kg hirudin/LPS | 11 | 2.7 (1.3) | 29.2 (28.8) | ND | ND | ND |
| Par1/Par2 high-dose LPS | ||||||
| wt, no pretreatment/LPS | 6 | 22.5 (3.68) | 23.4 (10.5) | 17.7 (6.44) | 64.0 (18.0) | 816 (307) |
| ko, no pretreatment/LPS | 7 | 137 (41.0)† | 69.3 (95.8) | 64.8 (63.5) | 137 (136) | 1811 (2057) |
| Par1/Par2 low-dose LPS | ||||||
| wt, no pretreatment/LPS | 5 | 131 (91.5) | 28.4 (22.2) | 3.83 (2.03) | 43.8 (31.9) | 305 (117) |
| ko, no pretreatment/LPS | 5 | 60.3 (25.5) | 43.7 (27.0) | 11.6§ (5.52) | 83.0 (40.0) | 443 (214) |
| Fibrin(ogen) low-dose LPS | ||||||
| wt, no pretreatment/LPS | 5 | 29.4 (6.92) | 35.4 (47.7) | 42.3 (69.9) | 118 (165) | 575 (313) |
| ko, no pretreatment/LPS | 5 | 37.5 (17.3) | 43.2 (46.8) | 23.9 (17.4) | 67.3 (45.3) | 442 (214) |
Treatments and genotype by sex and strain . | No. of mice . | TAT, ng/mL (SD) . | IL-6, ng/mL (SD) . | MIP-2, ng/mL (SD) . | MCP-1, ng/mL (SD) . | IL-10, pg/mL (SD) . |
|---|---|---|---|---|---|---|
| F, C57BL/6 | ||||||
| Thrombin inhibition, high-dose LPS | ||||||
| wt, saline/saline | 8 | 1.6 (0.96) | 0 (7.6) | 0 (3.4) | 0.27 (0.38) | 13.7 (5.9) |
| wt, saline/LPS | 8 | 78.5 (43.1) | 406 (325) | 151 (92.5) | 568 (551) | 793 (432) |
| wt, 5 mg/kg hirudin/LPS | 7 | 0.78 (0.37)* | 484 (333) | 199 (82.5) | 729 (589) | 1109 (458) |
| Thrombin inhibition, low-dose LPS | ||||||
| wt, saline/LPS | 8 | 48.7 (30.0) | 142 (84.4) | 94.2 (68.8) | 205 (120) | 781 (318) |
| wt, 1 mg/kg hirudin/LPS | 8 | 14.2 (3.96)* | 65.9 (27.7) | 39.5 (19.6) | 104 (32.9) | 865 (284) |
| wt, 5 mg/kg hirudin/LPS | 6 | 4.29 (0.49)* | 88.7 (61.5) | 50.6 (40.0) | 112 (45.8) | 1188 (1072) |
| Par2/Par4 low-dose LPS | ||||||
| wt: no pretreatment/LPS | 6 | 80.6 (32.0) | 57.7 (48.7) | 31.3 (29.4) | 167 (96.2) | 1101 (579) |
| ko: no pretreatment/LPS | 7 | 91.7 (52.9) | 44.5 (11.7) | 36.9 (23.6) | 133 (54.3) | 932 (423) |
| Thrombocytopenia low-dose LPS | ||||||
| wt, control serum/LPS | 8 | 64.8 (19.0) | 67.5 (36.7) | 47.2 (32.9) | 113 (58.4) | 905 (491) |
| wt, antiplatelet serum/LPS | 8 | 72.6 (13.9) | 110 (40.5) | 53.8 (19.7) | 139 (29.9) | 1464 (731) |
| M, 129/C57BL/6 | ||||||
| Thrombin inhibition PAR2 littermates, low-dose LPS | ||||||
| wt, 1 mg/kg hirudin/LPS | 11 | 2.8 (1.5) | 34.2 (29.5) | ND | ND | ND |
| ko, 1 mg/kg hirudin/LPS | 11 | 2.7 (1.3) | 29.2 (28.8) | ND | ND | ND |
| Par1/Par2 high-dose LPS | ||||||
| wt, no pretreatment/LPS | 6 | 22.5 (3.68) | 23.4 (10.5) | 17.7 (6.44) | 64.0 (18.0) | 816 (307) |
| ko, no pretreatment/LPS | 7 | 137 (41.0)† | 69.3 (95.8) | 64.8 (63.5) | 137 (136) | 1811 (2057) |
| Par1/Par2 low-dose LPS | ||||||
| wt, no pretreatment/LPS | 5 | 131 (91.5) | 28.4 (22.2) | 3.83 (2.03) | 43.8 (31.9) | 305 (117) |
| ko, no pretreatment/LPS | 5 | 60.3 (25.5) | 43.7 (27.0) | 11.6§ (5.52) | 83.0 (40.0) | 443 (214) |
| Fibrin(ogen) low-dose LPS | ||||||
| wt, no pretreatment/LPS | 5 | 29.4 (6.92) | 35.4 (47.7) | 42.3 (69.9) | 118 (165) | 575 (313) |
| ko, no pretreatment/LPS | 5 | 37.5 (17.3) | 43.2 (46.8) | 23.9 (17.4) | 67.3 (45.3) | 442 (214) |